An Investigator-Initiated Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of CGRP Antagonists in Patients With Dry Eye Disease and Asthenopia
Latest Information Update: 07 Jun 2024
At a glance
- Drugs Galcanezumab (Primary) ; Ubrogepant (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
Most Recent Events
- 07 Jun 2024 Status changed from recruiting to completed.
- 13 Jun 2023 New trial record